Evommune EVMN
NYSE EVMN
$8.31 -0.08 (-0.95%)
As of: Sep 29, 2026 · 3:59 PM EDT

Evommune (EVMN) Common Equity (2024 - 2026)

Updated

Evommune's Common Equity was $277.59 million in Q2 2026, compared with -$171.23 million a year earlier and down 8.9% from the prior quarter.

Analysis

Evommune (EVMN) Common Equity (2024 - 2026) Analysis & Trends

At the end of FY2025, Common Equity at Evommune came in at $205.57 million.

  • In earlier years, Common Equity was -$144.24 million in FY2024.
  • Quarterly Common Equity has moved between -$183.14 million (Q3 2025) and $304.56 million (Q1 2026) over five years.
  • Per Business Quant data, EVMN's Common Equity in the three quarters before Q2 2026 was $304.56 million (Q1 2026), $205.57 million (Q4 2025) and -$183.14 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 84.97 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -5.94 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 41.98 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 41.95 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 50.37 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 11.69 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 11.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 85.49 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 20.25 Bn
10 Evommune 304.40 Mn -333.11 Mn - 277.59 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 277.59 Mn
Mar 31, 2026 304.56 Mn
Dec 31, 2025 205.57 Mn
Sep 30, 2025 -183.14 Mn
Jun 30, 2025 -171.23 Mn
Mar 31, 2025 -158.24 Mn
Dec 31, 2024 -144.24 Mn
Sep 30, 2024 -122.53 Mn
API Access

Evommune Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=EVMN&period=max&api_key=YOUR_API_KEY